表紙
市場調査レポート

肺動脈性高血圧症 : パイプライン分析

Pulmonary Arterial Hypertension - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213126
出版日 ページ情報 英文 202 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
肺動脈性高血圧症 : パイプライン分析 Pulmonary Arterial Hypertension - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 202 Pages
概要

肺動脈性高血圧症とは、肺動脈(心臓から肺に、酸素吸入用の血液を送る動脈)内部の血圧が上昇するという疾患です。主な症状には、倦怠感やめまい、失神の発作、胸部の圧迫感・痛み、足首・脚部の腫れもの(浮腫)、息切れ(呼吸困難)などがあります。主な治療薬には抗凝結剤や利尿剤、血管拡張薬などがあります。

当レポートでは、世界各国での肺動脈高血圧症(PAH)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

肺動脈性高血圧症の概要

治療薬の開発

  • 肺動脈性高血圧症向けパイプライン製品:概要
  • 肺動脈性高血圧症向けパイプライン製品:比較分析

各企業で開発中の肺動脈性高血圧症治療薬

大学/研究機関で研究中の肺動脈性高血圧症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

肺動脈性高血圧症治療薬:開発中の製品の一覧(企業別)

肺動脈性高血圧症治療薬:研究中の製品の一覧(大学/研究機関別)

肺動脈性高血圧症治療薬の開発に従事している企業

  • APT Therapeutics, Inc.
  • Arena Pharmaceuticals, Inc.
  • 旭化成ファーマ
  • Ascendis Pharma A/S
  • Bial - Portela & Ca, S.A.
  • Cardioxyl Pharmaceuticals, Inc.
  • Carolus Therapeutics, Inc.
  • Celsion Corporation
  • Corridor Pharmaceuticals Inc.
  • Cytokinetics, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Insmed Incorporated
  • Lacer, S.A.
  • LTT Bio-Pharma Co., Ltd.
  • Mezzion Pharma Co. Ltd.
  • miRagen Therapeutics, Inc.
  • 日本新薬
  • Novartis AG
  • Peloton Therapeutics, Inc.
  • PharmaIN Corporation
  • PhaseBio Pharmaceuticals, Inc.
  • Pluristem Therapeutics Inc.
  • Proteo, Inc.
  • Pulmokine, Inc.
  • Reata Pharmaceuticals, Inc.
  • Respira Therapeutics, Inc.
  • Sagene Pharmaceuticals, Inc.
  • Silence Therapeutics Plc
  • Sinoxa Pharma GmbH
  • SteadyMed Therapeutics, Inc.
  • Suda Ltd
  • 東レ

肺動脈性高血圧症:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • (allopurinol + apocynin)
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • がん・肺動脈性高血圧症(PAH)向け抗体
  • 肺動脈性高血圧症向け抗体
  • APT-102
  • バルドキソロンメチル
  • beraprost sodium ER
  • beraprost sodium SR
  • BIA-51058
  • CT-2009
  • 肺動脈性高血圧症向けノッチ3受容体拮抗薬
  • ファスジル
  • GS-4997
  • メシル酸イマチニブ
  • INS-1009
  • LA-419
  • リスリド
  • MFC-001
  • MFC-002
  • 肺動脈性高血圧症向け Endothelin-1阻害用オリゴヌクレオチド
  • 肺動脈性高血圧症向けMicroRNA-145阻害用オリゴヌクレオチド
  • 肺動脈性高血圧症向けmiR-145阻害用オリゴヌクレオチド
  • PB-1046
  • PB-1120
  • 肺動脈性高血圧症向けウロテンシン-II受容体拮抗ペプチド
  • PGC-VIP
  • PK-10453
  • PK-10571
  • PLX-PAD
  • PT-2977
  • QCC-374
  • R-190
  • ralinepag
  • RT-234
  • セレギリン+PDE-5阻害剤
  • セレキシパグ
  • 肺動脈性高血圧症向け小分子
  • 血管機能不全・肺動脈性高血圧症・勃起障害向けアルギナーゼ阻害薬
  • 慢性閉塞性肺疾患(COPD)・ぜんそく・肺動脈性高血圧症向けミオシン阻害用小分子
  • 肺動脈性高血圧症向け可容性エポキシドヒドロラーゼ阻害薬
  • 肺動脈性高血圧症向けACE2活性化用小分子
  • 肺動脈性高血圧症向け5-HT1B作動小分子
  • SPI-054
  • SPI-183
  • SUD-004
  • タクロリムス
  • タダラフィル
  • tiprelestat
  • TPN-171
  • TR-422
  • トレプロスチニル
  • treprostinil diolamine
  • TXA-127
  • ウデナフィル

肺動脈性高血圧症治療薬:パイプライン製品の最新動向

肺動脈性高血圧症治療薬:開発が休止状態の製品

肺動脈性高血圧症治療薬:開発が中止された製品

肺動脈性高血圧症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース
  • ■付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7707IDB

Summary

Global Markets Direct's, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2016', provides an overview of the Pulmonary Arterial Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension
  • The report reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Pulmonary Arterial Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Choroidal Neovascularization Overview
  • Therapeutics Development
    • Pipeline Products for Choroidal Neovascularization - Overview
    • Pipeline Products for Choroidal Neovascularization - Comparative Analysis
  • Choroidal Neovascularization - Therapeutics under Development by Companies
  • Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes
  • Choroidal Neovascularization - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Choroidal Neovascularization - Products under Development by Companies
  • Choroidal Neovascularization - Products under Investigation by Universities/Institutes
  • Choroidal Neovascularization - Companies Involved in Therapeutics Development
    • Affitech A/S
    • F. Hoffmann-La Roche Ltd.
    • Genentech, Inc.
    • Iconic Therapeutics, Inc.
    • Mabion SA
    • Navigen Pharmaceuticals, Inc.
    • Noxxon Pharma AG
    • Promedior, Inc.
    • Sanwa Kagaku Kenkyusho Co., Ltd.
  • Choroidal Neovascularization - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antisense Oligonucleotides for Ophthalmology and Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AP-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Doxarubicin Pegylated - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hI-con1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-30D8 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NAV-2729 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Netrin-4 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NM-9405 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NOXD-20 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PGN-635 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRM-167 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranibizumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RG-7716 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SK-1011 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides for Age Related Macular Degeneration and Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Choroidal Neovascularization - Recent Pipeline Updates
  • Choroidal Neovascularization - Dormant Projects
  • Choroidal Neovascularization - Discontinued Products
  • Choroidal Neovascularization - Product Development Milestones
    • Featured News & Press Releases
      • Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance
      • Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
      • May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Choroidal Neovascularization, H1 2016
  • Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Choroidal Neovascularization - Pipeline by Affitech A/S, H1 2016
  • Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Choroidal Neovascularization - Pipeline by Genentech, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Iconic Therapeutics, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Mabion SA, H1 2016
  • Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H1 2016
  • Choroidal Neovascularization - Pipeline by Promedior, Inc., H1 2016
  • Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H1 2016
  • Choroidal Neovascularization - Dormant Projects, H1 2016
  • Choroidal Neovascularization - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Choroidal Neovascularization, H1 2016
  • Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top